August 1-2 | Hilton Motif Seattle + Virtually

Registered for the conference? View it here

Tuesday, August 1

(All times are in PT)

Breakfast Reception (in-person attendees)

7 - 8 a.m.

Welcome to the Spotlight on Immuno-Oncology

8 - 8:10 a.m.
Hans-Peter Kiem, MD, PhD
Fred Hutchinson Cancer Center

B-Cell Malignancies and Beyond

8:10 - 8:35 a.m.
Anna Truppel-Hartmann, MD
2seventy bio
Data from Phase 3 Clinical Trial for Multiple Myeloma

8:35 - 9 a.m.
Michael Jensen, MD
Seattle Children's Research Institute
Manufacturing Process Modulates CAR T Cell Efficacy and Fitness in Pediatric Subjects

9 - 9:25 a.m.
Carl June, MD
University of Pennsylvania
CAR T Cell Clinical Trials

9:25 - 9:50 a.m.
Rayne Rouce, MD
Baylor College of Medicine
CAR T for T-Cell Malignancies

9:50 - 10:05 a.m.
Biao Zheng, MD
BRL Medicine Inc.
High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Novel CAR Designs and Approaches

10:05 - 10:15 a.m.

10:15 - 10:40 a.m.
Robbie Majzner, MD
Stanford University
Novel CAR Designs

10:40 - 11:05 a.m.
Michel Sadelain, MD, PhD
Memorial Sloan Kettering Cancer Center
AG Sensitivity and T Cell Persistence

11:05 - 11:30 a.m.
Yvonne Chen, PhD
Engineering Next-Generation CAR-T Cells for Cancer Immunotherapy

11:30 - 11:55 a.m.
Jardin Leleux, PhD
2seventy bio
RESET: A novel drug-regulated, TCR-coupled antigen receptor architecture

11:55 a.m. - 12:10 p.m.
Maik Luu, PhD
University Hospital Wurzburg
Microbial Metabolites Guide the Engineering and Epigenetic-Metabolic Reprogramming of CAR T Cells for the Treatment of Solid Tumors

12:10 - 1 p.m.

TCR-Based Cancer Immunotherapy

1 - 1:25 p.m.
Chiara Bonini, MD
Vita-Salute San Raffaele University
TCR and Inhibitory Receptor Genome Editing

1:25 - 1:50 p.m.
Aude Chapuis, MD
Fred Hutchinson Cancer Research Center
All-hands on deck: Can we overcome the challenges associated with T cell receptor-based therapies?

1:50 - 2:15 p.m.
Chris Klebanoff, MD
Memorial Sloan Kettering Cancer Center
Immunogenicity and Therapeutic Targeting of Recurrently Mutated “Public” Neoantigens Using TCR Gene Therapy

2:15 - 2:40 p.m.
Dirk Busch, MD
Technical University of Munich
Advanced TCR engineering for polyclonal repertoire analysis and adoptive T cell therapy

2:40 - 2:55 p.m.
Elise Wilcox, PhD
Fred Hutchinson Cancer Center
Identification of Peptides Derived from Alternative Splicing for TCR-T Cell Therapies and Cancer Vaccines

Direct In Vivo Delivery

2:55 - 3:05 p.m.

3:05 - 3:30 p.m.
Saar Gill, MBBS, PhD, FRACP
University of Pennsylvania
Direct in vivo transduction of CAR T cells

3:30 - 3:55 p.m.
Ed Rebar, PhD
Sana Biotechnology
In Vivo Engineering for Cancer Immunotherapy

3:55 - 4:20 p.m.
Frederic Thalheimer, PhD
T Cell-Specific in vivo CAR-Delivery

4:20 - 4:45 p.m.
Andrew Scharenberg, MD
Direct In Vivo Delivery

4:45 - 5 p.m.
Philip Johnson, MD
Interius Bio
Targeted in Vivo Generation of CAR T and NK Cells Utilizing an Engineered lEntiviral Vector Platform

5 - 6:30 p.m.
Poster viewing & reception

Wednesday, August 2

Genome and Epigenome Editing for Cancer Immunotherapy 

8 - 8:25 a.m.
Pietro Genovese, PhD
Harvard Medical School
Epitope Editing of Hematopoietic Stem Cells to Enable Adoptive Immunotherapies for Acute Myeloid Leukemia

8:25 - 8:50 a.m.
Justin Eyquem, PhD
Bridging Synthetic Immunology and Genome Editing to advance T Cell Therapies 

8:50 - 9:15 a.m.
Jamie Schafer, PhD
Chroma Medicine
Using Epigenetic Editing to Engineer CAR T Cells

9:15 - 9:40 a.m.
Kole Roybal, PhD
Towards the Development of Synthetic Immunity to Cancer

9:40 - 9:55 a.m.
Xiaomeng Hu
Sana Biotechnology
CD47 Enhances CAR T Survival in NSG Recipients and Allogeneic Mice

Beyond T Cells

9:55 - 10:05 a.m.

10:05 - 10:30 a.m.
Paula Cannon, PhD
University of Southern California
Engineering B cells to express fully customizable antibodies

10:30 - 10:55 a.m.
Bob Valamehr, PhD
Fate Therapeutics, Inc.
iPSC-derived CAR T cells Uniformly Carrying Multiple Synthetic Modalities for the Off-the-Shelf Treatment of Cancer

10:55 - 11:20 a.m.
Michael Hudecek, MD
University Hospital Wurzburg
Minicircles & Transposon for T Cell Production

11:20 - 11:45 a.m.
Catherine Bollard, MD
The George Washington University
Native T-Cells for Adoptive Cell Therapy

11:45 a.m. - 12: 00 p.m.
Joshua Krueger
University of Minnesota
CD70 Knockout Provides Increased NK Cell Proliferation In Vivo



Register for the ASGCT Policy Summit

September 23-24, 2024 | Washington, D.C.

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.